List of Quillivant Xr drug patents

Quillivant Xr is owned by Nextwave.

Quillivant Xr contains Methylphenidate Hydrochloride.

Quillivant Xr has a total of 7 drug patents out of which 0 drug patents have expired.

Quillivant Xr was authorised for market use on 27 September, 2012.

Quillivant Xr is available in for suspension, extended release;oral dosage forms.

Quillivant Xr can be used as treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2, method of treating attention deficit hyperactivity disorder by administering the composition of claim 1, treatment of a patient by administering the formulation recited in claim 1 or claim 23.

The generics of Quillivant Xr are possible to be released after 15 February, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062667 NEXTWAVE Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(6 years from now)

US8778390 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8956649 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8465765 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US9040083 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8287903 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

US8563033 NEXTWAVE Orally effective methylphenidate extended release powder and aqueous suspension product
Feb, 2031

(8 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2012

Treatment: Treatment of a patient by administering the formulation recited in claim 1 or claim 23; Method of treating attention deficit hyperactivity disorder by administering the composition of claim 1; Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

How can I launch a generic of QUILLIVANT XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in